Article in BioStock / Immunicum gears up for second half of 2020

  • 15:49

BioStock today published an exclusive interview with our interim CEO, Alex Karlsson-Parra, reflecting on Immunicum’s achievements in 2020 including the presentation of the full and updated survival results from the Phase II MERECA study and the #RMAT designation by the FDA for ilixadencel in metastatic RCC, independent of the combination. The full article and Alex’ view on what’s to come for the remainder of the year can be accessed here:

Alex Karlsson-Parra